Kyorin Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kyorin Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12329
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:48
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kyorin Pharmaceutical Co Ltd (Kyorin), a subsidiary of Kyorin Holdings Inc, is a pharmaceutical company that manufactures and markets prescription medicines. The company offers ethical drugs including mucodyne, kipres, desalex, flutiform, pentasa, ketas and uritos. Its ketas product is a phosphodiesterase inhibitor agent for ameliorating bronchial asthma and cerebro-vascular disorders. Kyorin’s kipres is a bronchial asthma and allergic rhinitis therapeutic drug; and pentasa is an agent for ulcerative colitis and chrohn’s disease. It offers consumer healthcare products such as milton and milton CP and OTC drugs. The company collaborates with other companies to develop new medicine. It has operations in the US and Germany. Kyorin is headquartered in Tokyo, Japan.

Kyorin Pharmaceutical Co Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Licensing Agreements 23
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
Kyorin Pharma Enters into Licensing Agreement with Merck 24
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 27
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 28
Kyorin Pharma Enters into Licensing Agreement with Merck 29
Asset Transactions 30
Galderma Acquires Pekiron Cream From Kyorin Pharma 30
Kyorin Pharmaceutical Co Ltd – Key Competitors 31
Kyorin Pharmaceutical Co Ltd – Key Employees 32
Kyorin Pharmaceutical Co Ltd – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Product News 34
11/01/2017: MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 28th International Symposium on ALS/MND in Boston, MA, USA 34
10/28/2017: Cleveland Clinic trial on drug shows promise in slowing progressive multiple sclerosis 35
04/25/2017: MediciNova Announces Exploratory Interim Clinical Outcomes Data from Clinical Trial of MN-166 (ibudilast) in ALS Presented at the American Academy of Neurology 69th Annual Meeting in Boston 36
04/09/2017: MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois 38
02/27/2017: MediciNova Announces MN-166 (ibudilast) Glioblastoma Abstract Selected for Presentation at the 5th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies in Zurich, Switzerland 39
02/07/2017: MediciNova Announces MN-166 ALS Abstract Accepted for Presentation at the American Academy of Neurology (AAN) 69th Annual Meeting in Boston 40
Clinical Trials 41
Oct 26, 2017: MediciNova Announces Positive Top-Line Results from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS: Achieved Both Primary Endpoints including a Significant Reduction in Whole Brain Atrophy and Safety and Tolerability 41
Sep 19, 2017: MediciNova Announces the Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence 42
Aug 30, 2017: MediciNova Announces the Abstract from the MN-166 SPRINT-MS Phase 2b Study in Progressive MS – including Top Line Data – was Selected as a Platform Presentation for Late-Breaking Presentation at the 7th Joint ECTRIMS – ACTRIMS Meeting on October 28, 2017 in Paris, France 43
Jun 05, 2017: MediciNova Announces Positive Results from a Glioblastoma Animal Model Study Presented at the 2017 American Society of Clinical Oncology Annual Meeting 44
Feb 06, 2017: MediciNova Announces Positive Findings from Completed Trial of MN-166 (ibudilast) in Methamphetamine Dependence Presented at the 50th Winter Conference on Brain Research 45
Jan 23, 2017: MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48

List of Tables
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kyorin Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
Kyorin Pharma Enters into Licensing Agreement with Merck 24
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 27
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 28
Kyorin Pharma Enters into Licensing Agreement with Merck 29
Galderma Acquires Pekiron Cream From Kyorin Pharma 30
Kyorin Pharmaceutical Co Ltd, Key Competitors 31
Kyorin Pharmaceutical Co Ltd, Key Employees 32
Kyorin Pharmaceutical Co Ltd, Other Locations 33
Kyorin Pharmaceutical Co Ltd, Subsidiaries 33

List of Figures
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kyorin Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Kyorin Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cutispharma Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary CutisPharma Inc (CutisPharma) is a pharmaceutical company that develops and distributes kits. The company offers products such as oral suspensions, suppositories, oral solutions, and topical, among others. Its oral solutions and oral suspensions include mouthwashes, anti-microbial, and PPIs; …
  • Dr. Ci:Labo Co., Ltd.:企業の戦略・SWOT・財務情報
    Dr. Ci:Labo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dr. Ci:Labo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Rutherford Electric Membership Corp:企業の戦略的SWOT分析
    Rutherford Electric Membership Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Aerin Medical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Aerin Medical Inc (Aerin) develops a non-invasive medical device that treats nasal obstruction and breathing disorders. The company develops VIVAER, an advanced treatment platform that treats nasal congestion and remodel nasal soft tissues utilizing low-power radio frequency energy. Its trea …
  • Chang Hwa Commercial Bank, Ltd.:企業の戦略・SWOT・財務分析
    Chang Hwa Commercial Bank, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Chang Hwa Commercial Bank, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Verrica Pharmaceuticals Inc (VRCA):製薬・医療:M&Aディール及び事業提携情報
    Summary Verrica Pharmaceuticals Inc (Verrica) is a clinical-stage medical dermatology company that discovers, develops and commercializes therapeutics for the treatment of skin diseases. The company’s lead product candidate, VP-102, is in two phase 3 clinical trials for the treatment of molluscum co …
  • Crowley Maritime Corp:企業の戦略的SWOT分析
    Crowley Maritime Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • RCR Tomlinson Ltd (RCR):企業の財務・戦略的SWOT分析
    RCR Tomlinson Ltd (RCR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Pioneer Energy Services Corp (PES):企業の財務・戦略的SWOT分析
    Pioneer Energy Services Corp (PES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Concordia International Rx UK Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Concordia International Rx UK Ltd (Concordia International), formerly Amdipharm Mercury Company Ltd, a subsidiary of Concordia International Corp, is a manufacturer of pharmaceutical products and orphan drugs. The company’s products include acetazolamide, adenosine, adrenaline acid tartrate, …
  • Atossa Genetics Inc:企業のM&A・事業提携・投資動向
    Atossa Genetics Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Atossa Genetics Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Imbalie Beauty Limited:企業の戦略・SWOT・財務情報
    Imbalie Beauty Limited - Strategy, SWOT and Corporate Finance Report Summary Imbalie Beauty Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Intellipharmaceutics International Inc (IPCI):企業の財務・戦略的SWOT分析
    Intellipharmaceutics International Inc (IPCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Henry Lamotte Group:戦略・SWOT・企業財務分析
    Henry Lamotte Group - Strategy, SWOT and Corporate Finance Report Summary Henry Lamotte Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Gooderson Leisure Corporation Limited:企業の戦略・SWOT・財務情報
    Gooderson Leisure Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Gooderson Leisure Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • Biogen Inc (BIIB):企業の財務・戦略的SWOT分析
    Biogen Inc (BIIB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Toronto Hydro Corp:企業の戦略的SWOT分析
    Toronto Hydro Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • PSA Peugeot Citroen S.A. (PSA Groupe):戦略・SWOT・企業財務分析
    PSA Peugeot Citroen S.A. (PSA Groupe) - Strategy, SWOT and Corporate Finance Report Summary PSA Peugeot Citroen S.A. (PSA Groupe) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • BioElectron Technology Corp-製薬・医療分野:企業M&A・提携分析
    Summary BioElectron Technology Corp(BioElectron) formerly known as Edison Pharmaceuticals Inc, discovers and develops shared (redox) disease drugs. The company’s pipeline products comprise EPI-743, a drug candidate for inherited mitochondrial diseases and EPI-589 drug candidate entering phase 1 clin …
  • A. Menarini Industrie Farmaceutiche Riunite Srl:製薬・医療:M&Aディール及び事業提携情報
    Summary A. Menarini Industrie Farmaceutiche Riunite Srl (Menarini), formerly Farmacia Internazionale, is a biopharmaceutical company that undertakes the research, development and manufacture of several pharmaceutical products in various dosage forms. The company’s products portfolio is focused on a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆